Stockreport

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com